Thompson Davis & Co’s Karyopharm Therapeutics KPTI Stock Holding History

Thompson Davis & Co’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	$2K	Hold	8	–	–	﹤0.01%	667
2018 Q2	$2K	Hold	8	–	–	﹤0.01%	615
2018 Q1	$2K	Buy	+8	New	+$1.59K	0.01%	567
2017 Q2	–	Sell	-17	Closed	-$3K	–	1131
2017 Q1	$3K	Buy	+17	New	+$2.73K	﹤0.01%	997
2015 Q2	–	Sell	-17	Closed	-$8K	–	1223
2015 Q1	$8K	Buy	17 +9	+113%	+$3.88K	0.01%	789
2014 Q4	$5K	Buy	+8	New	+$4.54K	0.01%	928

Other funds holding KPTI

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Thompson Davis & Co's KPTI Position: Q3 2018 in Review

Thompson Davis & Co held its Karyopharm Therapeutics (KPTI) position steady in Q3 2018 at 8 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #667.

Thompson Davis & Co first reported a position in KPTI in Q4 2014 and has held it in 6 quarters since. The position peaked at $8K in Q1 2015. 119 funds tracked by Wall St. Rank hold KPTI as of Q3 2018.

Thompson Davis & Co held 8 shares of Karyopharm Therapeutics worth $2K as of Q3 2018.
Thompson Davis & Co left its Karyopharm Therapeutics share count unchanged in Q3 2018.
Karyopharm Therapeutics made up ﹤0.01% of Thompson Davis & Co's portfolio in Q3 2018, its #667 holding.
Thompson Davis & Co first reported a position in Karyopharm Therapeutics in Q4 2014 and has held it in 6 quarters since.
Thompson Davis & Co's Karyopharm Therapeutics position peaked at $8K in Q1 2015.
119 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2018.

Based on Thompson Davis & Co's 13F filing for Q3 2018, filed 14 Nov 2018.